Invesaro

Stocks Comparison

Niagen Bioscience vs Usana Health Sciences: revenue, profit, margins and growth compared

Niagen Bioscience brought in $129.4M of revenue in fiscal 2025, Usana Health Sciences $925.3M in fiscal 2025. Revenue changed by +29.9% at Niagen Bioscience and +8.3% at Usana Health Sciences on the year before, so Niagen Bioscience grew faster. Niagen Bioscience kept 13.4% of its revenue as net profit, Usana Health Sciences 1.2%.

Side by side, latest fiscal year

NAGEUSNA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (January 3, 2026)
Revenue$129.4M$925.3M
Revenue growth+29.9%+8.3%
Net income$17.4M$10.8M
Net margin13.4%1.2%
Free cash flown/a$8.5M
Free cash flow marginn/a0.9%
Earnings per share (diluted)$0.20$0.58
Cash$64.8M$158.4M
Debtn/an/a
Price to earnings15.325.0
Market value$241.3M$267.9M
Dividend yieldn/an/a
Rank by revenue in sector#282 of 523 · Health care#150 of 523 · Health care

Over the years

Revenue
NAGE FY2018: $31.6MNAGE FY2019: $46.3MNAGE FY2020: $59.3MNAGE FY2021: $67.4MNAGE FY2022: $72.1MNAGE FY2023: $83.6MNAGE FY2024: $99.6MNAGE FY2025: $129.4MUSNA FY2018: $1.2BUSNA FY2019: $1.1BUSNA FY2020: $1.1BUSNA FY2022: $1.2BUSNA FY2022: $998.6MUSNA FY2023: $921MUSNA FY2023: $854.5MUSNA FY2025: $925.3MFY18FY19FY20FY21FY22FY23FY24FY25
NAGE $129.4MUSNA $925.3M
Net income
NAGE FY2018: -$33.3MNAGE FY2019: -$32.1MNAGE FY2020: -$19.9MNAGE FY2021: -$27.1MNAGE FY2022: -$16.5MNAGE FY2023: -$4.9MNAGE FY2024: $8.6MNAGE FY2025: $17.4MUSNA FY2018: $126.2MUSNA FY2019: $100.5MUSNA FY2020: $124.7MUSNA FY2022: $116.5MUSNA FY2022: $69.4MUSNA FY2023: $63.8MUSNA FY2023: $42MUSNA FY2025: $10.8MFY18FY19FY20FY21FY22FY23FY24FY25
NAGE $17.4MUSNA $10.8M
Net margin
NAGE FY2018: -105.6%NAGE FY2019: -69.4%NAGE FY2020: -33.6%NAGE FY2021: -40.2%NAGE FY2022: -23.0%NAGE FY2023: -5.9%NAGE FY2024: 8.6%NAGE FY2025: 13.4%USNA FY2018: 10.6%USNA FY2019: 9.5%USNA FY2020: 11.0%USNA FY2022: 9.8%USNA FY2022: 6.9%USNA FY2023: 6.9%USNA FY2023: 4.9%USNA FY2025: 1.2%FY18FY19FY20FY21FY22FY23FY24FY25
NAGE 13.4%USNA 1.2%
Revenue growth
NAGE FY2019: +46.7%NAGE FY2020: +28.0%NAGE FY2021: +13.8%NAGE FY2022: +6.8%NAGE FY2023: +16.0%NAGE FY2024: +19.2%NAGE FY2025: +29.9%USNA FY2019: -10.8%USNA FY2020: +7.0%USNA FY2022: +4.6%USNA FY2022: -15.8%USNA FY2023: -7.8%USNA FY2023: -7.2%USNA FY2025: +8.3%FY19FY20FY21FY22FY23FY24FY25
NAGE +29.9%USNA +8.3%
Free cash flow
NAGE FY2018: -$22.2MNAGE FY2019: -$21.2MUSNA FY2018: $140.7MUSNA FY2019: $110.2MUSNA FY2020: $145.3MUSNA FY2022: $108.5MUSNA FY2022: $93.5MUSNA FY2023: $56.1MUSNA FY2023: $50.9MUSNA FY2025: $8.5MFY18FY19FY20FY22FY23FY25
NAGE -$21.2MUSNA $8.5M

Fiscal years as each company reports them; the two may end in different months.

Questions about Niagen Bioscience and Usana Health Sciences

Which is bigger by revenue, Niagen Bioscience or Usana Health Sciences?

Usana Health Sciences is bigger by revenue: $925.3M in fiscal 2025, against $129.4M for Niagen Bioscience in fiscal 2025.

Which keeps more of its revenue as profit, Niagen Bioscience or Usana Health Sciences?

Niagen Bioscience had a net margin of 13.4% in fiscal 2025; Usana Health Sciences had 1.2% in fiscal 2025.

Which grew revenue faster, Niagen Bioscience or Usana Health Sciences?

In their latest fiscal years revenue changed by +29.9% at Niagen Bioscience and +8.3% at Usana Health Sciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies